This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Cardiovascular diseases and their thrombotic complications remain the leading cause of death in industrialized nations. The need for better treatments has led to the development of safer, more potent drugs with more favorable pharmacokinetic profiles than those already available. DZ-697b is a newly developed, orally active, anti-platelet drug with possibly a faster onset of action and a lower variability in response compared to existing therapies. It is our objective to investigate the antithrombotic effects of this new agent and compare it to clopidogrel 300mg, using an ex vivo model of thrombosis.Hypothesis: The anti-platelet drug DZ-697b will result in reduction of acute thrombus formation in the Badimon Perfusion Chamber from baseline values, and the reduction will be equal to or better than those obtained with clopidogrel.
Showing the most recent 10 out of 869 publications